Subject: TDS
CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference
LOS ANGELES, March 16, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, Advisor to the Chairman and CEO, will present at the 28th Annual Oppenheimer Healthcare Conference on Wednesday, March 21, 2018 at 3:55 P.M. Eastern Daylight Time at the Westin New York Grand Central in New York, New York.
A live and archived webcast of the presentation will be available at: https://www.veracast.com/webcasts/opco/healthcare2018/58216302815.cfm
About the 28th Annual Oppenheimer Healthcare Conference
Investors will have the opportunity to hear and meet face to face with over 100 corporate management leaders from public and private companies at the forefront of the biopharmaceutical, biotechnology, medical device, life science tools and diagnostics, health technology and distribution, and healthcare facility, provider and service industries. There will also be presentations regarding emerging market opportunities and the current mergers and acquisitions climate. This significant two-day Conference of established institutional clients of Oppenheimer & Co. will be held at the Westin New York Grand Central in New York, New York for two days from Tuesday, March 20, 2018 through Wednesday, March 21, 2018.
About the LADRtm Technology Platform
CytRx's innovative LADRtm (Linker Activated Drug Release) technology platform employs a broad portfolio of novel linker molecules that selectively bind to circulating albumin and can be linked to a wide variety of anti-cancer payloads. The Company's research efforts currently center on creating new molecules from the combination of ultra-high potency cytotoxic payloads with tunable linkers. The molecules that CytRx is currently evaluating concentrate at the tumor site providing targeted delivery of the cell killing payloads.
About CytRx Corporation
CytRx Corporation (NASDAQ: CYTR) is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. CytRx is rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADRtm (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. Aldoxorubicin, CytRx's most advanced drug conjugate, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell, Inc.; our ability to develop new ultra-high potency drug candidates based on our LADRTM technology platform; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll/Sean Augustine-Obi
(212) 600-1902
[email protected]
[email protected]
SOURCE CytRx Corporation
These press releases may also interest you
|
News published on and distributed by:
